Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung squamous cell carcinoma||not applicable||CX-2029||Case Reports/Case Series||Actionable||In a Phase I/II trial (PROCLAIM-CX-2029), CX-2029 treatment resulted in partial response in a patient with squamous cell carcinoma of the lung (J Clin Oncol 38: 2020 (suppl; abstr 3502); NCT03543813).||detail...|
|PubMed Id||Reference Title||Details|
|CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer.||Full reference...|